{"nctId":"NCT01384539","briefTitle":"Vitamin D and Arterial Function in Patients With Chronic Kidney Disease","startDateStruct":{"date":"2011-07","type":"ACTUAL"},"conditions":["Arterial Dysfunction","Chronic Kidney Disease"],"count":128,"armGroups":[{"label":"Cholecalciferol","type":"EXPERIMENTAL","interventionNames":["Drug: Cholecalciferol"]},{"label":"Calcitriol","type":"EXPERIMENTAL","interventionNames":["Drug: Calcitriol"]}],"interventions":[{"name":"Cholecalciferol","otherNames":[]},{"name":"Calcitriol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age â‰¥ 18 years\n* Chronic kidney disease stage IIIB or IV by 4 parameter Modified Diet in Renal Diseases Formula (Estimated Glomerular Filtration Rate \\[GFR\\] 44-15 ml/min/1.73m2)\n* Vitamin D (D2 + D3) deficient, defined as serum 25(OH)D level \\< 30 ng/mL\n* Corrected serum calcium \\< 10.2 mg/dL\n* Serum phosphate \\< 4.6 mg/dL\n* Serum albumin \\> 3.0 g/dL\n* Body mass index \\< 40 kg/m2\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Significant co-morbid conditions that lead the investigator to conclude that life expectancy is less than 1 year\n* Expected to undergo living related kidney transplant in next 6 months\n* Pregnant, breastfeeding, or unwilling to use adequate birth control\n* History of severe liver disease\n* Nephrotic range proteinuria (\\> 3.5 gm/day)\n* Use of active vitamin D analogs within 30 days of randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment.","description":"EDD will be measured by brachial artery flow-mediated dilation (FMD). The mean change in percent FMD from baseline will be documented.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"4.2"},{"groupId":"OG001","value":"0.3","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Compare the Efficacy of Calcitriol and Cholecalciferol Supplementation on Plasma Concentrations of C-reactive Protein","description":"Secondary aims are focused to explore whether vitamin D improves vascular endothelial function through decreases in inflammation","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare the Effect of Calcitriol and Cholecalciferol Supplementation on Vascular Endothelial Cell Expression of Nf-kB","description":"The effect of calcitriol and cholecalciferol supplementation will be evaluated calculating the mean change in total vascular endothelial cell NFkB expression. NFkB expression is given as arbitrary units and represent ratios of endothelial cell protein expression to human umbilical vein endothelial cell (HUVEC) expression in order to account for any variation in the staining procedure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.1"},{"groupId":"OG001","value":"-0.01","spread":"0.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":64},"commonTop":["Hypercalcemia"]}}}